Science Exchange
Summer 2011AcquiredPowering scientific outsourcing
Pressure-test this opportunity
Explore the risks and possibilities with a prompt for ChatGPT, Claude, or your agent.
Powering scientific outsourcing
Explore the risks and possibilities with a prompt for ChatGPT, Claude, or your agent.
Science Exchange set out to make outsourcing a scientific experiment as easy as buying anything online, and over thirteen years it learned that R&D procurement in big pharma is not a spot market — it's a high-trust, high-compliance enterprise workflow. Founded in 2011 by cancer biologist Elizabeth Iorns with Ryan Abbott and Dan Knox, it began as an online marketplace connecting scientists to contract research organizations and specialized labs that could run experiments for them.[1]
It raised $77.6 million from investors including Norwest and Y Combinator, and gradually evolved from an open marketplace into enterprise "supplier orchestration" software for life-sciences R&D.[3] In September 2024, the private-equity firm Waud Capital Partners acquired Science Exchange, and the founders stepped aside the following year.[2] The story is a study in how the "marketplace for X" thesis concedes, in regulated high-trust B2B, to enterprise-workflow reality — and how that slower, stickier business grinds toward a solid PE outcome rather than a fast breakout.
Elizabeth Iorns was a working scientist — a breast-cancer researcher — when she co-founded Science Exchange in 2011 with Dan Knox and Ryan Abbott, and her motivation came straight from the lab.[5] Getting an experiment done that your own lab couldn't run meant a slow, opaque hunt for the right facility, informal networks, and one-off negotiations. Iorns believed this friction slowed science itself and even contributed to the reproducibility crisis, and that a marketplace could make outsourcing experiments fast, transparent, and standardized.
Science Exchange came through Y Combinator's Summer 2011 batch with a compelling "Uber for science" framing: post the experiment you need, get matched to vetted providers, order and pay through the platform.[7] Iorns paired the company with a scientific mission, later running the Reproducibility Project: Cancer Biology, which reinforced the brand's credibility with researchers. The vision attracted strong investors and real usage. But as it moved toward its biggest potential customers — pharmaceutical and biotech companies — it met a procurement reality that a consumer-style marketplace couldn't fully serve, and the product had to change to match it.
Science Exchange started as a two-sided marketplace: on one side, scientists at universities, biotech, and pharma who needed experiments run; on the other, contract research organizations and specialized facilities offering thousands of services. A researcher could find a provider for a specific assay or study, request quotes, order, and pay — with the platform handling discovery, transactions, and some standardization.[1]
As it pursued large pharmaceutical customers, the product deepened into enterprise supplier-orchestration software. Big pharma doesn't buy experiments off a spot market; it manages a roster of qualified suppliers under contracts, with strict compliance, procurement rules, payments, and data requirements. Science Exchange built software to orchestrate that — onboarding and qualifying suppliers, managing contracts and payments, ensuring compliance, and giving R&D and procurement teams a system to run outsourced science at scale.[4] The open-matching, liquidity-driven marketplace gave way to a workflow-and-compliance platform wrapped around relationships pharma already had.
Science Exchange ultimately centered on large pharmaceutical and biotech R&D organizations that outsource significant experimental work — high-value, compliance-heavy enterprise customers.
Life-sciences R&D outsourcing is a very large market, but the buyers are relatively few, sophisticated, and slow-moving, and they buy through procurement, not a consumer-style marketplace.
Science Exchange competed with the status quo of manual procurement, in-house systems, and general procurement software, plus the CROs' own sales relationships.[3] The structural insight is that its early competitive premise — marketplace liquidity, matching new buyers to new sellers — mattered less than expected, because pharma's real need was orchestrating existing supplier relationships under compliance. The company's durable position became enterprise workflow software, where the moat is integration, compliance, and switching cost rather than network effects. That's a good business, but a slower, less explosive one than a marketplace breakout.
Science Exchange moved from marketplace transaction fees toward enterprise software and orchestration revenue, charging large customers to run their R&D outsourcing through its platform.[4] Enterprise life-sciences software is sticky and valuable — long contracts, deep integration, high switching costs — but the sales cycles are long and the customer count is limited, so growth compounds steadily rather than exponentially. Over thirteen years and $77.6 million, Science Exchange built a real, defensible enterprise business, and its eventual acquirer was a private-equity firm that values durable enterprise revenue — a fitting buyer for a company whose value lived in orchestration and compliance, not in marketplace network effects.[2]
The central mechanism is that in a regulated, high-trust B2B domain, the "marketplace for X" premise often has to give way to enterprise-workflow software. Science Exchange's early value proposition assumed the bottleneck was discovery and matching — liquidity between new buyers and sellers.[1] But pharma's actual bottleneck was orchestrating an existing web of qualified suppliers under strict compliance, contracts, and procurement rules. The value migrated from matching to workflow, so the company evolved into supplier-orchestration software. This isn't a failure — it's a common and often correct evolution — but it changes the shape and speed of the business from a fast, network-effect marketplace to a steady enterprise-software grind.
Selling into pharmaceutical R&D means long qualification cycles, compliance requirements, and cautious, relationship-driven buyers.[3] That reality both created the opportunity (the complexity is real and worth solving) and constrained the pace: thirteen years and $77.6 million reflect how long it takes to build trusted infrastructure for conservative, high-stakes customers. Founders drawn to important, hard, regulated problems should expect a marathon, not a sprint, and capitalize accordingly.
The endgame — acquisition by a private-equity firm rather than a strategic buyer or IPO — reflects what Science Exchange became: a steady, defensible enterprise-software business with sticky revenue.[2] PE firms specialize in exactly this profile: durable cash-generating software they can grow and optimize. The founders built something real and lasting, and moved on to new chapters, with the company positioned to continue under new ownership.[6] It's a solid outcome for a mission-driven, patient build.